Key Takeaways
- Resilient year, uneven recovery: FY24 revenue of ₹7,012 crore and EBITDA of ₹984 crore were delivered despite sluggish global demand, with discretionary segments recovering while agrochemicals remain under pressure.
- Agrochemical pain has a timeline: The agrochemical segment will stay challenging through H1 FY25, but management expects a good recovery in H2 and a return to near-normal by calendar year 2025.
- Capex cycle is peaking: FY25 capex is guided at ₹1,500-1,800 crore, with over half going to a new site, while FY26 capex will be upward of ₹1,000 crore but is not yet finalized.
- Margin uplift is structural but distant: Chloro Toluene and downstream projects carry structurally higher EBITDA margins, but the weighted-average margin improvement is expected only from FY26-27 onwards.
- What to watch next quarter: Whether Q1 FY25 volume growth materializes as guided, the pace of agrochemical stabilization, and any quantification of the new site's product slate.
Demand & Volume Trajectory
- Discretionary recovery underway: Demand recovered in dyes, pigments, specialty polymers and additives, while macro concerns persist in non-discretionary segments tied to agrochemicals and pharma intermediates.
- Agrochemical drag is product-specific: Nitro Toluene volumes were lower reflecting agrochemical pressure, and the dicamba intermediate dedicated plant saw no significant volume this quarter. Some products will pick up this quarter or next, but full normalization waits until calendar year 2025.
- Volume growth promised from Q1: Management expects quarter-on-quarter volume growth throughout FY25, with new project contributions kicking in from Q2 and making H2 volumes substantially higher.
- Domestic market declined but is less relevant: FY24 domestic revenue fell 11%, but only ~25% of products are for domestic consumption; the rest is direct or indirect export. Higher raw material prices in H2 reduced the impact on reported sales numbers.
- Freight costs passed through: Red Sea disruption increased freight costs in Q4, but the increase gets substantially passed on to customers and the component is relatively small versus turnover.
Gogri: "Agrochemical first half will be challenging. But I think in the second half, I think we should see a good recovery in agrochemical."
Project Pipeline & Capex
- Multiple projects commissioning in FY25: Gradual commissioning includes Acid Phase-2 capacity expansion, specialty chemicals blocks, ethylation, Nitro Toluene capacities and asset upgradation. Nitro Toluene and downstream commissioning is expected in Q2 FY25, with some volumes tied to agrochemical contracts.
- Chloro Toluene is the next leg: The initial phase of the Chloro Toluene project is projected to commence by FY26, with products carrying structurally higher EBITDA margins that will lift the weighted-average margin from FY26-27 onwards.
- New site dominates FY25 capex: More than 50% of the ₹1,500-1,800 crore FY25 capex goes to a new site, which will house a multipurpose plant potentially linked to existing value chains, Chloro Toluene, or stand-alone products. Zone 1, 2 and 3 expansions are more completion-oriented.
- FY26 capex floor set, details pending: FY26 capex will be upward of ₹1,000 crore, but numbers are not fully finalized and will be shared in the next couple of quarters.
- Newer projects are 50-50 import substitution and export: Projects from FY26 onwards are oriented roughly equally toward import substitution and export markets.
- Sunrise sectors at developmental stage: The company is looking at battery storage, chemical circularity and biochemistry, but no investing has started yet.
Gogri: "I think another additional 10% to 15% should be possible. So more towards INR 2,000 crores kind of a number should be possible from ongoing existing location expansion."
Contracts & Revenue Visibility
- First long-term contract ramping slowly: The ₹330 crore agrochemical intermediate contract delivered below ₹100 crore in FY24 due to agrochemical headwinds; FY25 is expected around ₹250 crore with ramp-up starting this year and full-year impact next year.
- Contract ramp-up drove Q4 volumes: Q4 revenue increase came from both regular volumes and long-term contract volumes.
- Nitric acid supply disruption hit NCB volumes: Lower Nitro Chloro Benzene volumes were partially impacted by nitric acid pressure during the quarter, though management said it is difficult to quantify the exact volume impact. A major supplier expansion is coming in FY26, and some other Indian nitric acid capacities may come up in FY25 to mitigate disruption.
Margins & Costs
- Gross margin improved on mix and efficiency: Product mix improvement and margin expansion across existing businesses helped lift gross margin, while the increase in other expenses was mainly freight costs passed to customers.
- Fixed overhead growth contained: Fixed overhead will not increase substantially, barring 5-7% for inflation; other expenses include variable components linked to volume such as freight, production costs, effluent treatment, power and labor.
- Peak EBITDA from existing assets: An additional 10-15% from current levels is possible, taking EBITDA toward ₹2,000 crore from ongoing existing-location expansion alone.
- Margin guidance for FY26-27 is directional, not quantified: Management stated that Chloro Toluene-range products carry structurally higher EBITDA margins and the weighted-average combined EBITDA percentage will increase from FY26-27 onwards, but did not give a specific margin target when asked.
Balance Sheet & Working Capital
- No significant debt reduction expected: Ongoing capex projects mean debt reduction from an overall basis will not happen; working capital optimization is ongoing.
- Interest costs have peaked: Interest rates have largely peaked and the cost of debt should remain fairly similar next year.
- Inventory timing shifted revenue: A couple of products scheduled for March shipment went out in April; average pricing in H2 was somewhat higher than H1 on input cost components.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 EBITDA | ₹1,450-1,700 crore, supported by discretionary recovery, emerging non-discretionary revival, and operating leverage | FY25 |
| FY25 capex | ₹1,500-1,800 crore on project expansions | FY25 |
| Volume growth | Quarter-on-quarter volume increase throughout FY25, with H2 substantially higher | Starting Q1 FY25 |
| Agrochemical recovery | Challenging H1, good recovery in H2; near-normal for all products | H2 FY25 / calendar year 2025 |
| Nitro Toluene commissioning | NT and downstream commissioning, some volumes tied to agrochemical contracts | Q2 FY25 |
| Chloro Toluene project | Initial phase commencement | FY26 |
| FY26 capex floor | Upward of ₹1,000 crore (not yet finalized) | FY26 |
| Peak EBITDA from existing assets | Additional 10-15%, toward ₹2,000 crore | From ongoing existing-location expansion |
| Weighted-average EBITDA margin uplift | Structurally higher margins from Chloro Toluene range products lift combined percentage | FY26-27 onwards |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue (consolidated) | ₹1,955 cr, +3.5% QoQ |
| Revenue (full year FY24) | ₹7,012 cr |
| EBITDA including other income | ₹283 cr, +5.6% QoQ |
| EBITDA (full year FY24) | ₹984 cr, consistent with guidance |
| Profit after tax | ₹132 cr, +6.5% QoQ |
| Profit after tax (full year FY24) | ₹416 cr |
| EBITDA guidance for FY25 | ₹1,450–1,700 cr |
| Volume growth guidance for FY25 | 20%–30%, increased from earlier 20%–25% |
| CAPEX incurred in FY24 | over ₹1,280 cr |
| CAPEX planned for FY25 | ₹1,500–1,800 cr |
| Domestic : exports mix | 52 : 48 |
| Nitrochlorobenzene production | 17,646 metric tons, vs 18,842 MT in Q4 FY23 and 19,580 MT in Q3 FY24 |
| Nitrotoluene production | 6,675 metric tons, vs 6,130 MT in Q4 FY23 and 6,951 MT in Q3 FY24 |
| Hydrogenation output | 3,389 tonnes per month, vs 3,315 TPM in Q4 FY23 and 3,644 TPM in Q3 FY24 |
| PDA volumes | 523 tons per month |
| Discretionary : non-discretionary mix | 65 : 35 (agro and pharma at 35%) |
| Cost of debt | 7.5%–8% |
| Tax rate guidance for FY25–FY26 | 12%–16% |
| Dividend recommended for FY24 | ₹1 per share (20%) |